Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Biogen Inc. (BIIB) is conducting a study titled A Randomized, Open-Label, 2-Arm, 2-Part, Parallel Group Study to Assess the Pharmacokinetic Comparability of Subcutaneously Administered Litifilimab (BIIB059) Delivered by 3 Devices (Pre-Filled Syringe, Autoinjector, or On-Body Injector) in Healthy Participants. The study aims to evaluate how the body processes litifilimab when administered under the skin using three different devices, focusing on pharmacokinetic comparability, safety, and tolerability.
The intervention involves the drug litifilimab, delivered through three devices: a pre-filled syringe (PFS), an autoinjector (AI), and an on-body injector (OBI). These devices aim to facilitate easier administration, especially for patients with limited hand mobility or needle anxiety.
The study is interventional, with a randomized, parallel assignment model and no masking. Its primary purpose is treatment. Participants are divided into two parts: Part 1 compares AI and PFS, while Part 2 compares OBI and PFS. The study spans approximately 22 weeks per participant, including an 8-day initial stay and a 17-week follow-up.
The study began on January 2, 2025, with the last update on August 19, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates for stakeholders.
The study’s outcome could influence Biogen’s stock performance and investor sentiment, given the potential for innovative drug delivery methods to enhance patient compliance and treatment efficacy. Competitors in the pharmaceutical industry may also be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.